HBM7004 can now enter clinical development in both China and the United States after NMPA and FDA IND clearances, putting Harbour BioMed’s B7H4-dependent T-cell engager into its first human test.
Harbour BioMed and Sinopharm form a biologics R&D consortium spanning antibody discovery, clinical development, manufacturing and commercialisation.
Harbour BioMed expects up to $67 million interim profit as antibody deals lift revenue, but margin trends will shape the next investor debate.
Read how Harbour BioMed’s Amgen patent win could reshape antibody discovery licensing, biologics IP and biotech investor sentiment.
Find out how Harbour BioMed’s HBM7004 China IND acceptance could reshape B7-H4 solid tumor immunotherapy development.
Solid tumor T-cell engagers still face safety limits. Harbour BioMed’s HBM7004 now tests whether B7-H4 can widen that window.
Harbour BioMed’s HBM9378 Phase I data shows long half-life and safety. Find out what this means for asthma, COPD, and TSLP competition.
Harbour BioMed acquires stake in Spruce Biosciences, reinforcing its SPR202 collaboration. Find out what this signals for CRH-targeted therapies.
Harbour BioMed has signed a global strategic collaboration and license agreement with Bristol Myers Squibb to discover and develop next-generation multispecific antibodies. The deal could be worth over $1.1 billion across upfront payments, milestones, and royalties. It also signals growing interest in platforms capable of generating novel immunotherapies for complex diseases. The announcement is not